Mosaic ImmunoEngineering Inc. (CPMV) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Huntington Beach, CA, United States. El CEO actual es Steven W. King.
CPMV tiene fecha de IPO 2013-01-02, 2 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $5.03M.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
